Glenmark Pharmaceuticals – Manufacturer of Medicines
Glenmark
Glenmark Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1977 by Gracias Saldanha and headquartered in Mumbai. Its shares are listed on India's NSE and BSE stock exchanges.
Glenmark makes generic and branded medicines and runs its own research. Its main areas are dermatology, respiratory care and oncology, and its portfolio also covers diabetes and cardiovascular disease. One of its own products is Ryaltris (olopatadine and mometasone), a nasal spray for allergic rhinitis approved by the US FDA.
Innovative oncology research is concentrated in its subsidiary Ichnos Glenmark Innovation, formed in 2024. In 2025 Glenmark signed a licensing agreement with AbbVie for ISB 2001, an investigational multiple myeloma drug, with an upfront payment of 700 million US dollars.
Glenmark has plants in India, the US, Argentina and the Czech Republic. In 2024 it sold a 75% stake in its active ingredient maker, Glenmark Life Sciences, to Nirma. Glenmark medicines are sold in more than 80 countries.
Unifarm carries Glenmark medicines: Nindanib (nintedanib), Evermil (everolimus), Abirapro (abiraterone) and Aprezo (apremilast).